News
CRMD
8.42
-1.40%
-0.12
These 10 small-cap U.S. healthcare giants rank among the market's most attractively valued stocks
Seeking Alpha · 4d ago
Weekly Report: what happened at CRMD last week (0525-0529)?
Weekly Report · 4d ago
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
Seeking Alpha · 05/27 17:36
Weekly Report: what happened at CRMD last week (0518-0522)?
Weekly Report · 05/25 09:35
Cormedix Earnings Call Highlights Surging Growth, New Risks
TipRanks · 05/20 01:21
CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat
Seeking Alpha · 05/18 14:09
Weekly Report: what happened at CRMD last week (0511-0515)?
Weekly Report · 05/18 09:34
Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA), Cormedix (CRMD) and AnaptysBio (ANAB)
TipRanks · 05/15 15:20
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Cormedix (CRMD) and Biogen (BIIB)
TipRanks · 05/15 12:50
CorMedix to join RBC Capital Markets Global Healthcare Conference fireside chat
PUBT · 05/15 12:31
RBC Capital Keeps Their Buy Rating on Cormedix (CRMD)
TipRanks · 05/15 11:09
Cormedix Earnings Call Highlights Growth, Raises Outlook
TipRanks · 05/15 00:08
CorMedix (CRMD) Q1 2026 Earnings Transcript
NASDAQ · 05/14 18:44
CorMedix Shares Climb With Higher 1Q Profit, Sales
Dow Jones · 05/14 18:44
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Cormedix (CRMD)
TipRanks · 05/14 18:00
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
Benzinga · 05/14 17:54
Analyst Reiterates Buy on Cormedix, Maintains Unchanged $13 Price Target Amid Strengthening Commercial Execution and Pipeline Prospects
TipRanks · 05/14 16:46
Cormedix outlines $325M-$345M 2026 net revenue outlook amid TDAPA transition
Seeking Alpha · 05/14 16:41
3 Low P/E Stocks with Over 40% Upside
TipRanks · 05/14 15:30
Cormedix Raises FY2026 Sales Guidance from $300.000M-$320.000M to $325.000M-$345.000M vs $308.224M Est
Benzinga · 05/14 13:28
More
Webull provides a variety of real-time CRMD stock news. You can receive the latest news about Cormedix through multiple platforms. This information may help you make smarter investment decisions.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.